On March 15, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, "Sporos" or the "Company"), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, reported that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place April 14-19, 2023, in Orlando, FL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting preclinical data on our TEAD inhibitor, which we believe has best-in-class potential based on its optimized TEAD isoform selectivity profile and resultant preclinical activity superior to that of other compounds in development," said Stephen Rubino, Ph.D., Sporos’ Chief Executive Officer. "SPR1 inhibitors show single-agent activity against multiple TEAD-dependent cell lines in vitro and in vivo, including a range of non-NF2 mutation cell lines and those cell lines that are simply YAP-hyperactive. In addition, our differentiated TEAD inhibitors have demonstrated potent synergistic activity in combination with inhibitors of the MAPK pathway, creating the potential for broad applicability across a number of cancers with serious unmet medical need."

Presentation Details:

Title: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM – 5:00 PM
Abstract Number: 445

(Press release, Sporos BioDiscovery, MAR 15, 2023, View Source [SID1234662123])

On March 15, 2023 AimedBio and Genequantum healthcare reported the preclinical study result of co-developing FGFR3-ADC ‘AMB302/GQ1011’ will be presented at the "World ADC".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– They have confirmed AMB302/GQ1011’s anti-tumor effect in both bladder cancer and GBM cancer models, and plan to submit IND and start phase 1 clinical trial in 1H 2024.

(Press release, AimedBio, MAR 15, 2023, View Source;s_keyword=&s_where=&start=20 [SID1234656921])

On March 15, 2023 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") reported that the Phase Ib/II clinical study of the Company’s self-developed ADCC-enhanced CTLA-4 antibody drug (project number: IMM27M) jointly with Tislelizumab targeting PD-1 in patients with advanced solid tumors was approved by the National Medical Products Administration (NMPA), which is another milestone in the Company’s development (Press release, ImmuneOnco Biopharma, MAR 15, 2023, View Source [SID1234655685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMM27M is an IgG1 antibody against the CTLA-4 target. It has been genetically engineered to significantly enhance the ADCC activity. Compared with the same drug Ipilimumab, the drug effect in animals is significantly better than Ipilimumab at the same dose. At a lower dose (0.3mg/ kg) can completely remove the tumor.

The phase I dose-escalation clinical trial of the IMM27M project for solid tumors is progressing smoothly. The first patient has been administered in June 2022, and the 5mg/kg dose group has been achieved so far. Preliminary clinical data of the previous dose (3mg/kg) show that IMM27M is well tolerated, and there has been no dose-limiting toxicity (DLT) so far, and it has shown positive effects on some patients with advanced solid tumors (such as melanoma, breast cancer). The curative effect signal, after one to two cycles of treatment, the tumor shrunk by 22.8% and 28.7%, respectively.

Dr. Tian Wenzhi, Founder and Chairman of ImmuneOnco, said,

We are very pleased that our new generation of CTLA-4 antibody project IMM27M combined with tislelizumab has been approved by the NMPA for Phase Ib/II clinical trials in patients with advanced solid tumors. Repeated in vivo studies have demonstrated that IMM27M has a strong anti-tumor effect It is active and can be combined with multiple drugs in the company’s pipeline for clinical research. The dual-immune combination therapy of CTLA4 combined with PD1/PD-L1 has proven to have a clear clinical synergy. BMS’s ipilimumab combined with O. The indications have been approved by the FDA for marketing, covering multiple clinical indications such as melanoma, colorectal cancer, renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, etc. We believe that IMM27M will have great clinical development value. We will continue to advance the research of the IMM27M project and bring good news to the majority of cancer patients.

On March 15, 2023 Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, reported that it has added $12 million to its seed round, bringing the total amount to $20M (Press release, Protai Bio, MAR 15, 2023, View Source;bringing-the-total-to-20-million—to-build-an-oncology-drug-discovery-pipeline-301772904.html [SID1234647410]). The round includes existing investors Grove Ventures and Pitango HealthTech and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data acquisition as well as increase its discovery activities via pharma partnerships.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Genomic biomarkers are only relevant for approximately 15% of tumors, thus limited in use. Protein-level biomarkers can predict patient populations not seen by genomic means, by directly measuring proteins, their interactions, and their functions. To tap into the potential of protein-level data, Protai has built a proteomics AI-based platform that comprehensively maps the course of a disease on the protein level. Its technology allows it to better predict which patients will respond to a given drug, as well as discover novel drug targets that were missed by genomic approaches. These discoveries may be the key to significantly accelerating drug discovery and clinical development, lowering the time and costs of R&D.

Since its initial funding last year, Protai has opened laboratories at its Israel R&D center for data acquisition, biological validation and drug discovery activities and recruited an experienced drug discovery team with significant experience in successfully bringing drugs to the clinic. Additionally, Protai established collaborations with several leading hospitals, and now has access to over 100k well-defined banked samples for its comprehensive tumor mapping process, focused on gyno-oncology and lung cancer indications.

With the additional funding, Protai will expand its activities to include an oncology drug discovery pipeline, initially focusing on targets with a clearly-defined novel patient population biomarker, derived from its AI proteomics platform. To help navigate these efforts, the company has added Dr. Sharon Shacham, a serial biotech entrepreneur and Founder of Karyopharm Therapeutics, to Protai’s Board of Directors. In addition, Protai is supported by leading oncology experts, including Prof. Giulio Draetta, Chief Scientific Officer at MD Anderson and former Pharma executive; Prof. Bradley J. Monk, Director of Gynecologic Oncology at the University of Arizona College of Medicine; Prof. Funda Meric-Bernstam, Chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center, and Dr. Jurgen Moll, former Head Molecular Oncology, Sanofi Vitry. In addition,

"We are excited to announce this funding that supports our mission to enhance the drug development pathway from discovery through commercialization," said Eran Seger, CEO and co-founder of Protai. "I am extremely proud of our talented team and the achievements we have made to date. We look forward to scaling our organization and its important work towards revolutionizing the drug development landscape."

"Our investment in Protai highlights Maj Invest’s increasing investment in the Israeli tech ecosystem," said Jeppe Christian, CEO of Maj Invest Equity Fund. "We are excited to partner with this exceptional team, and we are positive that Protai will make a huge leap forward in how patients are treated and cured."

On March 15, 2023 Aptamer Science reported the company that it will participate in the American Association for Cancer Research (AACR) (Free AACR Whitepaper) and present research results on ‘CD25-ApDC immunotherapy’ (Press release, Aptamer Sciences, MAR 15, 2023, View Source;idx=234 [SID1234641617]). The presentation abstracts selected this time will be released on the AACR (Free AACR Whitepaper) official website on the 31st.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR is the world’s largest international cancer society where more than 20,000 researchers from over 120 countries gather every year to share cancer-related knowledge and clinical research.

This year, it will be held in Orlando, Florida, USA from April 14th to 19th (local time).

Aptamer Science plans to present research results on the topic of ‘Removal and inhibition of regulatory T cells by aptamer-drug transporter targeting human CD25’.

‘CD25-ApDC immune anti-cancer drug’ specifically binds to CD25 on regulatory T cells within tumors to prevent cancer cells from evading the body’s immune system.

In particular, CD25-ApDC not only selectively suppresses the function of Treg cells, but also promotes immune function by inducing the activation of cytotoxic T cells and antigen-labeling cells that prevent tumor growth.

The study on ‘CD25-ApDC immune anti-cancer drug’ presented at this conference has been selected for the National New Drug Development Industry hosted by the Korea New Drug Development Foundation (KDDF), and mechanism research and animal model evaluation are currently in progress at the lead material stage.

Lee Dae-gyeon, head of Aptamer Science Research and Development Division, said, "I believe that the presentation at this global conference will be an opportunity to verify the feasibility and competitiveness of aptamer-based immunotherapy research."

"Based on this, we plan to secure momentum for developing treatments and speed up development to conclude early partnerships in the future."

Go to article: Aptamer Science announces immunotherapy research results at AACR (Free AACR Whitepaper) in the U.S.